Posaconazole susceptibility testing against Candida species: Comparison of broth microdilution and E-test methods

Mycoses

Volumn 50, Issue 3, 2007, Pages 178-182

  Soczo G ^b   Kardos, G ^b   McNicholas, P M ^c   Falusi, E ^b   Gergely, L ^b   Majoros, L ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Candida; E test; Posaconazole activity; Solvent use; Susceptibility testing

Indexed keywords

MACROGOL; POSACONAZOLE; SOLVENT;

ARTICLE; BROTH MICRODILUTION METHOD; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS ISOLATION; GEOMETRY; IN VITRO STUDY; INTERMETHOD COMPARISON; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; DIMETHYL SULFOXIDE; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYETHYLENE GLYCOLS; SOLVENTS; TRIAZOLES;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA INCONSPICUA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 34247624625     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2007.01356.x     Document Type: Article

References (10)

1. Barchiesi F, Arzeni D, Fothergill AW et al. In vitro activities of the new antifungal triazole SCH-56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000 44 : 226 9.
2. Pfaller MA, Messer SA, Hollis RJ et al. In vitro activities of posaconazole (SCH 56592) compared with those of itraconazole and FLZ against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001 45 : 2862 4.
3. Pfaller MA, Messer SA, Mills K et al. Evaluation of E-test method for determining posaconazole MICs for 314 clinical isolates of Candida species. J Clin Microbiol 2001 39 : 3952 4.
4. Pfaller MA, Diekema DJ, Messer SA et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003 41 : 78 83.
5. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003 47 : 3149 54.
6. Groll AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 2005 3 : 467 87.
7. Segal BH, Barnhart LA, Anderson VL et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005 40 : 1684 8.
8. Al-Abdely HM, Alkhunaizi AM, Al-Tawfiq JA et al. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med Mycol 2005 43 : 91 95.
9. Majoros L, Kardos G, Szabó B et al. Fluconazole susceptibility testing of Candida inconspicua clinical isolates: comparison four method. J Antimicrob Chemother 2005 55 : 275 6.
10. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts - Second Edition: Approved Standard M27-A2. Wayne, PA, USA : NCCLS, 2002.